CoChat

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-33172-5

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 ARID1A and KRAS mutations are enriched in patients treated with cetuximab. a Number of patients with genomic alterations at either timepoint per treatment arm. Genomic alterations include non-synonymous single-nucleotide variants (SNV), indels, and gene rearrangements. Layered above the red bar is the corresponding percentage of patients with selected alterations, defined as an increase by 25 percentage points in the normalized MAF, calculated relative the highest reported MAF, between paired baseline and end of study cfDNA from 333 1L mCRC patients treated with either bevacizumab or cetuximab in combination with chemotherapy in the CALGB/SWOG 80405 trial. Asterisks indicate statistically significant differences (FDR p-value < 0.2) by two-tailed Fisher’s exact test, restricted to 18 genes with at least 2 selected alterations in either arm. b Distribution of the % change in relative MAF between baseline and end of study for all KRAS and ARID1A alterations detected in all patients. Dashed line represents 25% threshold used to call tumors with selected mutations. c Clinical information for patients with selected ARID1A and/or KRAS alterations. d Representative mutation evolution maps for cetuximab-treated patients with selected ARID1A mutations. The maximum observed % MAF is shown at the bottom for each timepoint. PRE, at baseline; OTH, on treatment; EOT, at progression or end of study.
Fig. 1 ARID1A and KRAS mutations are enriched in patients treated with cetuximab. a Number of patients with genomic alterations at either timepoint per treatment arm. Genomic alterations include non-synonymous single-nucleotide variants (SNV), indels, and gene rearrangements. Layered above the red bar is the corresponding percentage of patients with selected alterations, defined as an increase by 25 percentage points in the normalized MAF, calculated relative the highest reported MAF, between paired baseline and end of study cfDNA from 333 1L mCRC patients treated with either bevacizumab or cetuximab in combination with chemotherapy in the CALGB/SWOG 80405 trial. Asterisks indicate statistically significant differences (FDR p-value < 0.2) by two-tailed Fisher’s exact test, restricted to 18 genes with at least 2 selected alterations in either arm. b Distribution of the % change in relative MAF between baseline and end of study for all KRAS and ARID1A alterations detected in all patients. Dashed line represents 25% threshold used to call tumors with selected mutations. c Clinical information for patients with selected ARID1A and/or KRAS alterations. d Representative mutation evolution maps for cetuximab-treated patients with selected ARID1A mutations. The maximum observed % MAF is shown at the bottom for each timepoint. PRE, at baseline; OTH, on treatment; EOT, at progression or end of study.CC BY · PubMed Central
Fig. 2 ARID1A mutations confer poor outcome to cetuximab relative to bevacizumab possibly by partially inducing an EGFR transcriptional program. a Kaplan–Meier curves showing OS for 429 CALGB/SWOG 80405 patients with archival tissue available for targeted sequencing24, stratified by ARID1A mutation status and treatment arm. Patients with ARID1A alterations classified as known or likely were considered mutant. p-values from log-rank test shown. b Heatmap representation of the ARID1A mutant-like signature in 578 CALGB/SWOG 80405 patients with gene expression data. c Distribution of the ARID1A signature score in the discovery TCGA cohort and validation cohort CALGB/SWOG 80405 cohort stratified by ARID1A mutation status. p-values determined by two-sided Wilcoxon rank sum test. d ARID1A mutant-like signature score split into quartiles with the % of alterations in each quartile that were ARID1A mutant and WT in the 297 patients with both RNAseq and FMI mutation data available from the CALGB/SWOG 80405 cohort. e Distribution of MSigDB C6 Oncogenic signatures (GSVA scores) by ARID1A mutant-like signature group in CALGB/SWOG 80405. Two-sided Wilcoxon rank sum test; *p < 0.05, ***, p < 0.001. c, e The interquartile range (IQR) is depicted by the box with the median represented by the center line. Whiskers maximally extend to 1.5× IQR (with outliers shown). Source data are provided as a Source Data file.
Fig. 2 ARID1A mutations confer poor outcome to cetuximab relative to bevacizumab possibly by partially inducing an EGFR transcriptional program. a Kaplan–Meier curves showing OS for 429 CALGB/SWOG 80405 patients with archival tissue available for targeted sequencing24, stratified by ARID1A mutation status and treatment arm. Patients with ARID1A alterations classified as known or likely were considered mutant. p-values from log-rank test shown. b Heatmap representation of the ARID1A mutant-like signature in 578 CALGB/SWOG 80405 patients with gene expression data. c Distribution of the ARID1A signature score in the discovery TCGA cohort and validation cohort CALGB/SWOG 80405 cohort stratified by ARID1A mutation status. p-values determined by two-sided Wilcoxon rank sum test. d ARID1A mutant-like signature score split into quartiles with the % of alterations in each quartile that were ARID1A mutant and WT in the 297 patients with both RNAseq and FMI mutation data available from the CALGB/SWOG 80405 cohort. e Distribution of MSigDB C6 Oncogenic signatures (GSVA scores) by ARID1A mutant-like signature group in CALGB/SWOG 80405. Two-sided Wilcoxon rank sum test; *p < 0.05, ***, p < 0.001. c, e The interquartile range (IQR) is depicted by the box with the median represented by the center line. Whiskers maximally extend to 1.5× IQR (with outliers shown). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 ARID1A mutant-like signature enriches for cetuximab-resistant patients in eRAS/BRAF WT tumors. a Kaplan–Meier curves showing OS in n = 162 eRAS/BRAF WT patients stratified by ARID1A signature group (mutant-like vs. WT-like), using the signature score Q4 cutoff, and by treatment arm with p-values from log-rank test shown. b Clinical response (best RECIST) to cetuximab (top) and bevacizumab (bottom) was stratified by ARID1A mutant-like signature group for the n = 153 CALGB/SWOG 80405 eRAS/BRAF WT patients with RECIST response, RNAseq and FMI alterations data available. PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response. CR and PR cases were considered responders and SD and PD cases non-responders to treatment. a, b Source data are provided as a Source Data file. c, e Change in tumor volume from baseline to after 3 weeks on cetuximab treatment (20 mg/kg, twice a week) for 132 eRAS/BRAF WT PDX models shown by ARID1A signature group (c), and for all 244 PDX models shown by KRAS mutation status (e). p-values by two-sided Wilcoxon rank sum test (***p < 0.001). The interquartile range (IQR) is depicted by the box with the median represented by the center line. Whiskers maximally extend to 1.5× IQR (with outliers shown). d, f Cetuximab response by ARID1A signature group in the eRAS/BRAF WT population (d; n = 121) and by KRAS status in the full PDX cohort (f; n = 192).
Fig. 3 ARID1A mutant-like signature enriches for cetuximab-resistant patients in eRAS/BRAF WT tumors. a Kaplan–Meier curves showing OS in n = 162 eRAS/BRAF WT patients stratified by ARID1A signature group (mutant-like vs. WT-like), using the signature score Q4 cutoff, and by treatment arm with p-values from log-rank test shown. b Clinical response (best RECIST) to cetuximab (top) and bevacizumab (bottom) was stratified by ARID1A mutant-like signature group for the n = 153 CALGB/SWOG 80405 eRAS/BRAF WT patients with RECIST response, RNAseq and FMI alterations data available. PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response. CR and PR cases were considered responders and SD and PD cases non-responders to treatment. a, b Source data are provided as a Source Data file. c, e Change in tumor volume from baseline to after 3 weeks on cetuximab treatment (20 mg/kg, twice a week) for 132 eRAS/BRAF WT PDX models shown by ARID1A signature group (c), and for all 244 PDX models shown by KRAS mutation status (e). p-values by two-sided Wilcoxon rank sum test (***p < 0.001). The interquartile range (IQR) is depicted by the box with the median represented by the center line. Whiskers maximally extend to 1.5× IQR (with outliers shown). d, f Cetuximab response by ARID1A signature group in the eRAS/BRAF WT population (d; n = 121) and by KRAS status in the full PDX cohort (f; n = 192).CC BY · PubMed Central
Fig. 4 ARID1A mutations may compensate for mutant EGFR signaling by partially inducing an EGFR transcriptional program. a Overview of genes with SV or copy-number alterations (CN) that are mutual exclusive (ME, purple) or co-occurring (CO, green) with ARID1A SVs based on the SELECT method32, in a CRC (n = 16,931) and lung cancer (n = 29,757) cohort from the FMI FoundationCORE database38. Known and likely oncogenic alterations in each gene were considered for the SELECT analysis. Asterisks indicate significant relationships (FDR < 0.1). b Overview of significant interactions with ARID1A SVs detected in lung cancer (top) and CRC (bottom), ranked by SELECT scores. c Mutation occurrences for 5980 patients with ARID1A and/or EGFR mutations in the FMI lung cancer cohort. d Overview of known and likely EGFR (top) and ARID1A (bottom) mutations in lung cancer patients. aa amino acid.
Fig. 4 ARID1A mutations may compensate for mutant EGFR signaling by partially inducing an EGFR transcriptional program. a Overview of genes with SV or copy-number alterations (CN) that are mutual exclusive (ME, purple) or co-occurring (CO, green) with ARID1A SVs based on the SELECT method32, in a CRC (n = 16,931) and lung cancer (n = 29,757) cohort from the FMI FoundationCORE database38. Known and likely oncogenic alterations in each gene were considered for the SELECT analysis. Asterisks indicate significant relationships (FDR < 0.1). b Overview of significant interactions with ARID1A SVs detected in lung cancer (top) and CRC (bottom), ranked by SELECT scores. c Mutation occurrences for 5980 patients with ARID1A and/or EGFR mutations in the FMI lung cancer cohort. d Overview of known and likely EGFR (top) and ARID1A (bottom) mutations in lung cancer patients. aa amino acid.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 53

Metadata

Authors
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., Wang, L., Bourgon, R., de Sousa e Melo, F., Bolen, C., Daemen, A., Venook, A. P., Innocenti, F., Lenz, H.-J., & Bais, C.
Affiliations
  • Genentech (US)
  • Foundation Medicine (United States) (US)
  • Mayo Clinic (US)
  • Guardant (United States) (US)
  • University of California, San Francisco (US)
  • University of North Carolina at Chapel Hill (US)
  • USC Norris Comprehensive Cancer Center (US)
Corresponding author
  • Johnson, Radia M.
  • Qu, Xueping
  • Bais, Carlos
Venue
Nature Communications
Published
2022-09-19
Volume
13
Issue
1
Pages
5478-5478
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4296252900
Cited by
42
References
65
Citations by year
2026: 9 · 2025: 12 · 2024: 15 · 2023: 5 · 2022: 1
FWCI
3.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
ARID1A mutation, cetuximab resistance, colorectal cancer, anti-EGFR therapy, anti-VEGF therapy, bevacizumab, MAPK signaling, predictive biomarkers, epigenetic regulators, KRAS, BRAF, treatment resistance, lung cancer
MeSH terms
Cetuximab, Antineoplastic Agents, Immunological, DNA-Binding Proteins, Humans, Mutation, Transcription Factors, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41467-022-33172-5
The paper
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., Wang, L., Bourgon, R., de Sousa e Melo, F., Bolen, C., Daemen, A., Venook, A. P., Innocenti, F., Lenz, H.-J., & Bais, C. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. https://doi.org/10.1038/s41467-022-33172-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.